Taysha Gene Therapies Inc (NAS:TSHA)
$ 2.05 -0.1 (-4.65%) Market Cap: 413.83 Mil Enterprise Value: 369.69 Mil PE Ratio: 0 PB Ratio: 7.09 GF Score: 31/100

Taysha Gene Therapies Inc at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript

May 19, 2021 / 07:05PM GMT
Release Date Price: $21.78 (-0.05%)
Luca Issi
RBC Capital Markets, Research Division - Research Analyst

(technical difficulty)

here at RBC Capital Markets. And today, it's a great privilege to have R.A. Session, II, President, Founder and CEO of Taysha; and Suyash Prasad, CMO of Taysha as well for a fireside chat. Guys, how is it going today?

R. A. Session
Taysha Gene Therapies, Inc. - Founder, President, CEO & Director

Good, good. And we really appreciate being on with you today, Luca. So thank you to you and then the rest of the RBC team. It's been a great day.

Questions & Answers

Luca Issi
RBC Capital Markets, Research Division - Research Analyst

That's fantastic. Great to hear that. So maybe, R.A., let's start with the GAN opportunity here. Obviously, you've done a recent transactions there. You in-licensed the product there. Can you maybe just briefly recap the clinical data that you have seen today? And maybe bigger picture, if you can talk about why that transaction can be transformational for you and shareholders?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot